Shay Capital’s Corcept Therapeutics CORT Stock Holding History

Shay Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-350,000	Closed	-$7.58M	–	441
2023 Q1	$7.58M	Buy	+350,000	New	+$7.67M	1.49%	10

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Shay Capital's CORT Position: Q2 2023 in Review

Shay Capital sold out of Corcept Therapeutics (CORT) in Q2 2023, closing a stake of 350,000 shares — an estimated $7.58M sold.

Shay Capital first reported a position in CORT in Q1 2023 and held it in 1 quarter. The position peaked at $7.58M in Q1 2023. 224 funds tracked by Wall St. Rank hold CORT as of Q2 2023.

Shay Capital reported no remaining Corcept Therapeutics position as of Q2 2023 after selling out during the quarter.
Shay Capital sold 350,000 Corcept Therapeutics shares in Q2 2023, an estimated $7.58M.
Shay Capital first reported a position in Corcept Therapeutics in Q1 2023 and held it in 1 quarter.
Shay Capital's Corcept Therapeutics position peaked at $7.58M in Q1 2023.
224 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2023.

Based on Shay Capital's 13F filing for Q2 2023, filed 14 Aug 2023.